Zanubrutinib belongs to a class of targeted drugs known as Bruton’s tyrosine kinase inhibitors, or BTK inhibitors, which block a signaling protein that B cells, the immune cells that turn malignant in chronic lymphocytic leukemia, rely on for survival and proliferation. First-generation inhibitors such as ibrutinib transformed outcomes for this patient population but carried a burden of off-target effects, because they also inhibited related kinases including those involved in cardiac rhythm, platelet aggregation, and other signaling pathways. Zanubrutinib was engineered for greater selectivity, binding BTK more completely while sparing neighboring targets, and the new cohort study set out to test whether that improved pharmacological profile translates into better tolerability and sustained disease control outside the carefully curated environment of a clinical trial.

The researchers interrogated treatment patterns across the full cohort with unusual granularity. Therapy was discontinued in 76 patients, or 18.5 percent of the total, but the reasons tell an encouraging story. Disease progression accounted for only 32 discontinuations, or 7.8 percent of all patients, meaning the vast majority of patients who stopped the drug did so for reasons unrelated to treatment failure. Patient preference led 25 patients, or 6.1 percent, to discontinue, adverse events prompted 15 patients, or 3.7 percent, to stop, and four patients, or 1.0 percent, died of unknown causes. In an era when treatment duration on continuous oral therapy is a key measure of a drug’s real-world value, these numbers suggest that zanubrutinib keeps patients on treatment and keeps their disease in check for extended periods.

Perhaps the most clinically consequential finding concerns dose reductions, a topic that has generated anxiety among both oncologists and patients. Forty-six patients, or 11.2 percent of the cohort, required at least one dose reduction, most commonly because of adverse events, which affected 17 patients, or 4.1 percent, or because of patient preference, cited by 26 patients, or 6.3 percent. The critical question has always been whether lowering the dose compromises efficacy. The answer from this cohort appears to be no. Among the 46 patients who reduced their dose, the researchers observed no cases of disease progression or death after the reduction occurred, over a median follow-up of 10.9 months from the first dose modification. While the follow-up window is relatively short and the subgroup modest in size, the signal is reassuring for the many patients who need to taper their dose to manage side effects.

The study also shed light on a growing phenomenon in leukemia care: switching between BTK inhibitors. Fifty-four patients in the cohort moved to zanubrutinib from another BTK inhibitor without any evidence of disease progression, meaning they switched for tolerability or convenience rather than treatment failure. Thirty-two of these patients made the move because of adverse events on their previous drug, 19 because of patient preference, and four for unknown reasons, with some reasons overlapping. The median duration of zanubrutinib treatment after the switch was 10.1 months among patients who switched due to side effects and 16.5 months among those who switched by preference. Most notably, progression-free survival had not been reached in either group at the time of analysis, indicating that patients who transition from an older BTK inhibitor to zanubrutinib for non-progressive reasons can continue to achieve durable disease control on the newer agent.

From a technical standpoint, the study’s design merits attention. The investigators conducted a retrospective, multicenter cohort analysis drawing on data from hospitals across China, including Peking University People’s Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanfang Hospital, West China Hospital, and several others, with Peking University People’s Hospital serving as the central ethics committee. The primary endpoint was progression-free survival, the standard measure of how long patients live without their disease worsening, analyzed with confidence intervals to quantify uncertainty. The three-year PFS estimate of 91.6 percent for treatment-naive patients carried a 95 percent confidence interval of 83.8 to 95.8 percent, while the 83.2 percent estimate for later-line patients spanned 74.6 to 89.1 percent. These intervals, while wide in places due to the evolving follow-up time, place real-world outcomes squarely in the territory previously reported in registration trials, a consistency that strengthens confidence in the drug’s effectiveness.

The distinction between initial and later-line therapy matters enormously in chronic lymphocytic leukemia, an indolent malignancy that predominantly affects older adults and often follows a relapsing course over many years. Patients receiving zanubrutinib as initial therapy had not been exposed to prior BTK inhibition and typically had fewer accumulated resistance mechanisms. Those receiving it later had often been through chemoimmunotherapy or earlier targeted agents. The roughly eight-percentage-point gap in three-year progression-free survival between the two groups is consistent with the expected biology, yet the fact that later-line patients still achieved better than 83 percent freedom from progression at three years underscores how much the BTK inhibitor class has reshaped the prognosis of relapsed and refractory disease, which was historically one of the most difficult scenarios to manage.

Why does real-world evidence of this kind matter so much? Registration trials enroll selected patients, often excluding those with significant comorbidities, competing medications, or atypical disease features, and they monitor adherence intensively. Routine practice is different. Patients forget doses, stop drugs because they feel well, reduce doses on their own initiative, and switch therapies based on quality-of-life considerations that never appear in a case report form. By documenting that only 3.7 percent of patients discontinued zanubrutinib because of adverse events, and that dose reductions did not precipitate disease progression, this nationwide cohort provides the kind of pragmatic evidence that health systems, guideline committees, and prescribing physicians need when weighing treatment options for a disease that may require years of continuous oral therapy.

The findings also carry implications for how clinicians counsel patients about side effect management. Patient preference was the single most common reason for both dose reduction and discontinuation in this cohort, a reminder that shared decision-making is not a formality but a genuine determinant of treatment trajectories. Some patients in the study chose to reduce or stop their medication despite adequate tolerability, and the data suggest that, at least within the observed follow-up, such choices did not immediately translate into disease progression. That said, the authors and the broader hematology community would caution that longer observation is needed before dose attenuation can be considered fully equivalent to continuous full-dose therapy, particularly given the indolent nature of the disease and the possibility of late relapse.

Taken together, the study offers a comprehensive portrait of zanubrutinib as it is actually used: a drug with high selectivity for its target, low rates of discontinuation for toxicity, reassuring outcomes after dose modification, and strong progression-free survival in both first-line and later-line settings. As BTK inhibitors continue to evolve and as fixed-duration combinations challenge the paradigm of continuous therapy, cohorts like this one, registered as NCT06489184 on ClinicalTrials.gov, will remain essential for understanding how these powerful targeted agents perform in the hands of real patients and real physicians, far from the protocolized confines of the clinical trial.

Subject of Research: Real-world effectiveness, dose modification and discontinuation patterns of the BTK inhibitor zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort

Article References: Yang, S., Zhu, H., Hu, L., Feng, R., Guo, X., Niu, T., Shen, K., Li, Z., Dong, Y., Wang, B., Su, L., Wang, L., Wang, L., Sun, W., Fang, F., Zhao, Y., Huang, X., & Li, J. (2026). Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17043-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17043-6

Keywords: zanubrutinib, chronic lymphocytic leukemia, small lymphocytic lymphoma, BTK inhibitor, progression-free survival, dose reduction, real-world evidence, drug discontinuation, adverse events, hematology, targeted therapy, BMC Cancer

Bruton tyrosine kinase, or BTK, sits at a critical junction in the B-cell receptor signaling pathway, and blocking it cripples the survival machinery of malignant lymphocytes. The first-generation inhibitor ibrutinib proved the concept, improving progression-free survival in relapsed or refractory disease, but its off-target activity produced troublesome cardiac events, bleeding, and other toxicities. Second-generation inhibitors zanubrutinib and acalabrutinib were engineered for greater selectivity, and clinical momentum has been rapid: acalabrutinib combined with bendamustine and rituximab recently earned preferred first-line status in the NCCN 2025 guideline after the ECHO trial demonstrated a complete response rate of 88.9 percent and a median progression-free survival of 28.6 months, while zanubrutinib gained a first-line indication restricted to TP53-mutant disease after Phase II trials recorded complete response rates of 88 percent in that high-risk cohort. Yet guidelines remained fragmented, because trial designs varied so widely that head-to-head conclusions were impossible without pooling the evidence.

To close that gap, investigators systematically searched PubMed, Cochrane, and Embase for studies published before January 31, 2025, identifying thousands of records: 715 studies touching acalabrutinib, 3,398 on ibrutinib, and 486 on zanubrutinib. After duplicate removal and rigorous screening by independent reviewers, 70 studies survived, comprising four randomized controlled trials, three retrospective-prospective observational studies, and 63 single-arm cohort studies. Together they encompassed 1,641 treatment-naïve patients and 1,791 patients with relapsed or refractory disease, with median ages ranging from 56 to 75 years in the newly diagnosed group and 61 to 74 years in the relapsed group. The analysis was registered with PROSPERO, conducted under PRISMA reporting standards, and quality was assessed with the Cochrane Risk of Bias 2 tool for randomized trials and the MINORS instrument for single-arm studies. Statistical pooling used random-effect models where heterogeneity exceeded an I-squared value of 50 percent, with sensitivity analyses and funnel plots, Egger’s test, and Begg’s test confirming the absence of publication bias.

The headline results are striking. In treatment-naïve patients, BTK inhibitor-based therapy achieved a pooled complete response rate of 76.5 percent and an objective response rate of 94.5 percent. In relapsed or refractory patients, the corresponding figures fell to 43.2 percent and 81.2 percent, illustrating how much harder the disease is to subdue once it has already weathered prior treatment. Subgroup analysis by drug type then revealed a clear hierarchy in the newly diagnosed setting: zanubrutinib delivered a complete response rate of 95.2 percent, acalabrutinib 89.3 percent, and ibrutinib only 61.3 percent, a statistically significant difference with a p-value of 0.0042. Objective response rates followed the same pattern, at 99.1 percent for zanubrutinib, 97.7 percent for acalabrutinib, and 90.0 percent for ibrutinib. In the relapsed setting, however, the three drugs performed comparably, with no significant differences in either complete response or objective response rates.

Safety data from 53 studies added crucial nuance. Hematologic toxicities dominated, with pooled rates of neutropenia around 28 to 34 percent, thrombocytopenia around 33 to 35 percent, and anemia between 16 and 20 percent across patient groups. Zanubrutinib-based therapy showed significantly lower rates of neutropenia in treatment-naïve patients and lower thrombocytopenia in relapsed patients than its two rivals. Infection emerged as the most common non-hematologic adverse event, affecting roughly a third of newly diagnosed patients and nearly 40 percent of relapsed patients, and zanubrutinib carried a notably higher infection rate of 66.1 percent in the relapsed setting. Ibrutinib, by contrast, was associated with a significantly elevated rate of cardiac events at 7.7 percent, compared with just 2.0 percent for acalabrutinib and 0.2 percent for zanubrutinib, while acalabrutinib showed the lowest hemorrhage rate at 9.3 percent. These safety profiles, combined with superior efficacy, argue strongly for the newer agents in frontline care.

The analysis also dissected how best to combine BTK inhibitors with other therapies, a question that has generated considerable confusion in the clinic. In newly diagnosed patients, triple regimens pairing a BTK inhibitor with an anti-CD20 monoclonal antibody and small-molecule agents such as venetoclax, lenalidomide, or proteasome inhibitors achieved a complete response rate of 88.0 percent and an objective response rate of 97.1 percent, numerically outperforming regimens built on traditional chemotherapy with or without stem cell transplantation, though the difference did not reach statistical significance. In relapsed disease, the most impressive complete response rates came from combining BTK inhibitors with CAR T-cell immunotherapy at 80.0 percent, and with anti-CD20 antibodies plus small-molecule therapy at 68.3 percent, both significantly better than monotherapy. Because only 20 patients in the entire dataset received the BTK inhibitor plus CAR-T combination, the authors urge caution in interpreting that result, but the signal is compelling.

The findings carry substantial biological and clinical logic. BTK inhibitor monotherapy rarely achieves deep, durable remissions, and acquired resistance eventually defeats many patients, particularly in the relapsed setting. Pairing BTK blockade with agents attacking complementary pathways, such as the BCL2 inhibitor venetoclax or immunomodulators like lenalidomide, addresses that vulnerability. An observational cohort study cited in the analysis showed that BTK inhibitor-venetoclax regimens could overcome the unfavorable prognosis of TP53-mutated disease, and the ENRICH trial demonstrated that ibrutinib plus rituximab outperformed standard immunochemotherapy with fewer grade 3 or higher adverse events in untreated patients. The meta-analysis now provides quantitative support for chemotherapy-free strategies, showing that small-molecule combinations can match or exceed chemotherapy-based regimens without their cumulative toxicity, a potentially transformative option for elderly and frail patients who cannot tolerate intensive chemoimmunotherapy.

The authors are candid about limitations. Most included studies were single-arm trials vulnerable to selection bias; heterogeneity was moderate to high, reflecting differences in patient demographics, TP53 status, treatment line, and follow-up duration; and most studies did not report progression-free or overall survival in analyzable form, precluding pooled survival analysis and leaving long-term benefit unproven. Nonetheless, the central conclusions stand on robust methodology: acalabrutinib and zanubrutinib are more promising than ibrutinib as first-line options, owing to superior response rates and more favorable safety profiles, and chemotherapy-free combination regimens can partially overcome the traditionally grim prognosis of relapsed disease. As BTK inhibitors continue to infiltrate frontline protocols, this synthesis offers clinicians a data-driven roadmap for sequencing therapy, and it sets a clear agenda for the randomized head-to-head trials that the field still sorely needs.

Subject of Research: Comparative efficacy and safety of Bruton tyrosine kinase inhibitors in treatment-naïve and relapsed/refractory mantle cell lymphoma

Article Title: Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis

Article References: Xu, F., Zou, X., Yang, Y., Zhou, K., & Huang, W. (2026). Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis. Journal of Cellular and Molecular Medicine, 30(17), Article e71340. https://doi.org/10.1111/jcmm.71340

Image Credits: AI Generated

DOI: 10.1111/jcmm.71340

Keywords: mantle cell lymphoma, BTK inhibitors, acalabrutinib, zanubrutinib, ibrutinib, meta-analysis, clinical trials, hematology, chemotherapy-free regimens, lymphoma treatment, venetoclax, CAR-T therapy